Skip to main
RZLT
RZLT logo

Rezolute (RZLT) Stock Forecast & Price Target

Rezolute (RZLT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rezolute Inc. is advancing its clinical-stage biopharmaceutical efforts with promising results from its lead candidate, ersodetug, which has demonstrated substantial improvement in managing hypoglycemia and a favorable safety profile. Notably, discussions with key opinion leaders indicate that approximately 70% of congenital hyperinsulinism patients are unresponsive to standard of care treatments, suggesting a significant market opportunity for Rezolute's efficacious therapies. The company aims to leverage these clinical insights and ongoing research to create value and generate revenue through successful product development and regulatory approvals.

Bears say

The financial outlook for Rezolute Inc appears negative due to its reported 4Q25 net loss of $24.4 million, which aligns closely with consensus estimates of $25.9 million, indicating a lack of profitability. Further compounding the concern, the projected FY25 net loss is anticipated to reach $74.4 million, surpassing earlier consensus estimates of $95 million, reflecting ongoing financial strain. Additionally, potential regulatory delays stemming from FDA staffing issues could hinder the company's progress in obtaining necessary approvals for its drug candidates, adding to uncertainty in its financial future.

Rezolute (RZLT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rezolute (RZLT) Forecast

Analysts have given Rezolute (RZLT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Rezolute (RZLT) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rezolute (RZLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.